WHO ICTRP trial
JALSG-AML224-FLT3-ITD
JPRN-jRCTs041250036 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs041250036 |
|---|---|
| Public title | JALSG-AML224-FLT3-ITD |
| Scientific title | Open-label, Single-arm Study Evaluating the Efficacy and Safety of Quizartinib in Combination with Standard Chemotherapy in Patients with NewlyDiagnosed FLT3-ITD-positive Acute Myeloid Leukemia - JALSG-AML224-FLT3-ITD |
| Primary sponsor | Ishikawa Yuichi |
| Secondary sponsors | Kiyoi Hitoshi;Hanai Masaharu;Kodera Yasuhiro |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Conditions | Newly diagnosed FLT3-ITD-positive acute myeloid leukemia |
| Interventions | Following induction therapy with intensive chemotherapy, quizartinib is administered. In patients who achieve complete remission, up to four courses of high-dose cytarabine in combination with quizartinib are given during the consolidation… |
| Registration date | May 30, 2025 |
| Target size | 150 |
| Registry page | jrct.mhlw.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: